Tesamorelin
Metabolism + Body Composition
Body-composition research, with context.
A growth hormone-releasing factor analog with meaningful human evidence in a specific medical population. Understanding that context is essential to understanding the science.
Evidence reviewed October 2, 2026 · Educational overview
01 / THE COMPOUND
What is it?
Tesamorelin is an analog of growth hormone-releasing factor. A prescription formulation has an FDA-approved indication for excess abdominal fat in adults with HIV-associated lipodystrophy. That approval does not apply to PepTalk inventory. [1]
02 / THE OPPORTUNITY TO LEARN
Why researchers are interested
Different fat compartments
Clinical studies distinguish visceral fat around internal organs from subcutaneous fat beneath the skin. Tesamorelin research has focused on visceral adiposity in people with HIV-associated fat accumulation. [2]
Hormonal signaling
Its activity at pituitary growth hormone-releasing factor receptors connects it to growth hormone and IGF-1 biology. This does not establish a muscle-building benefit for healthy people. [1]
Beyond a single measurement
A smaller randomized trial also explored liver fat. These findings help generate questions about metabolic biology; they do not establish a general weight-loss or liver-treatment claim. [3]
03 / RESEARCH INTEREST
Follow the questions.
04 / THE BIOLOGY
How it works
- GHRF receptor signaling
- Growth hormone / IGF-1 axis
- Body-composition outcomes studied
Tesamorelin stimulates the release of endogenous growth hormone through the GHRF receptor. The approved product label describes increased IGF-1 and clinically important safety considerations. A pathway diagram is not a treatment recommendation. [1]
05 / PUBLISHED FINDINGS
What research has observed
Controlled human research
A randomized trial in 404 adults with HIV-associated abdominal fat accumulation found reduced visceral fat, with benefits lost after switching to placebo. Findings belong to the studied population and prescription formulation. [2]
Controlled human research
A 50-person randomized trial in adults with HIV and abdominal fat accumulation reported reductions in visceral and liver fat over six months. It called for further investigation of clinical importance and longer-term consequences. [3]
Established clinical indication
The FDA label is specific to HIV-associated lipodystrophy. It states that the prescription product is not indicated for weight-loss management; long-term cardiovascular safety is not established. [1]
06 / EVIDENCE SNAPSHOT
Different evidence. Different conclusions.
These descriptive labels summarize the selected evidence. They are not numerical quality scores or product ratings.
- Mechanistic research
- Defined hormonal signaling pathway
- Human research
- Randomized trials in specific clinical populations
- Therapeutic use
- Specific prescription indication; not general weight loss
07 / OPEN QUESTIONS
What we still don’t know
Findings cannot establish effectiveness in healthy adults seeking fat loss, performance, or muscle growth. The approved label includes risks such as glucose intolerance and elevated IGF-1, plus contraindications. Research inventory is not equivalent to an approved medicine. [1]
08 / GO TO THE SOURCE
Selected research
09 / TRACEABILITY
Testing & documentation
Published studies are not a Certificate of Analysis for our inventory.
No verified lot-specific reports have been supplied for this compound. Identity, assay, purity, laboratory, testing date, sterility, endotoxin, and expiration must be supported by the applicable record before a claim is shown.
10 / RESEARCH FORMATS
From the inventory
20 mg is listed in the inventory. This is not the FDA-approved product or an approved dosing format. Formulation, stock, and batch documentation await verification.
Inventory references: TESAMORELIN-20
Membership does not change the evidence or imply that ordering is available. Research information is not medical advice or a protocol for human use.